Oliver R. Mikse
YOU?
Author Swipe
View article: Supplementary Methods from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Supplementary Methods from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors Open
- PDF file 306K, MRI tumor volume quantification, lists for all the antibodies used in the experiments, gating method for Flow cytometry analysis, and supplementary references
View article: Supplementary Methods from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Supplementary Methods from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors Open
- PDF file 306K, MRI tumor volume quantification, lists for all the antibodies used in the experiments, gating method for Flow cytometry analysis, and supplementary references
View article: Supplementary Table 1 from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Supplementary Table 1 from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors Open
- PDF file 57K, Supplementary table and legend. Evaluation of the PD-L1 expression in tumor samples carrying EGFR mutations
View article: Supplementary Table 1 from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Supplementary Table 1 from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors Open
- PDF file 57K, Supplementary table and legend. Evaluation of the PD-L1 expression in tumor samples carrying EGFR mutations
View article: Data from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Data from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors Open
The success in lung cancer therapy with programmed death (PD)-1 blockade suggests that immune escape mechanisms contribute to lung tumor pathogenesis. We identified a correlation between EGF receptor (EGFR) pathway activation and a signatu…
View article: Supplementary Figures from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Supplementary Figures from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors Open
- PDF file 2020K, Supplementary figures 1-11. For the mouse experiments tumor bearing lungs were classified as mildly sick and severely sick based on the tumor burden as determined by right lung lobe weights. Oncogene induced immunosuppres…
View article: Data from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Data from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors Open
The success in lung cancer therapy with programmed death (PD)-1 blockade suggests that immune escape mechanisms contribute to lung tumor pathogenesis. We identified a correlation between EGF receptor (EGFR) pathway activation and a signatu…
View article: Supplementary Figures from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Supplementary Figures from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors Open
- PDF file 2020K, Supplementary figures 1-11. For the mouse experiments tumor bearing lungs were classified as mildly sick and severely sick based on the tumor burden as determined by right lung lobe weights. Oncogene induced immunosuppres…
View article: Supplementary Figure Legends from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Supplementary Figure Legends from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors Open
- PDF file 92K, Legends to supplementary figures 1-11
View article: Supplementary Figure Legends from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Supplementary Figure Legends from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors Open
- PDF file 92K, Legends to supplementary figures 1-11
View article: Data from Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in <i>ALK</i>-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance
Data from Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in <i>ALK</i>-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance Open
Purpose: To extend the results of a phase III trial in patients with non–small cell lung cancer with adenocarcinomas harboring EML4-ALK fusion.Experimental Design: We conducted a co-clinical trial in a mouse model comp…
View article: Data from Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in <i>ALK</i>-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance
Data from Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in <i>ALK</i>-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance Open
Purpose: To extend the results of a phase III trial in patients with non–small cell lung cancer with adenocarcinomas harboring EML4-ALK fusion.Experimental Design: We conducted a co-clinical trial in a mouse model comp…
View article: Supplementary Figures 1 - 3 from Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in <i>ALK</i>-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance
Supplementary Figures 1 - 3 from Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in <i>ALK</i>-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance Open
PDF file - 806K, Supplemental Figure 1. MRI scans at the indicated time points showing tumor burden in EML4-ALK lung cancer mice treated by crizotinib. Multiple scans from a total of 4 mice are shown. Supplemental Figure 2. Representative …
View article: Supplementary Figures 1 - 3 from Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in <i>ALK</i>-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance
Supplementary Figures 1 - 3 from Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in <i>ALK</i>-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance Open
PDF file - 806K, Supplemental Figure 1. MRI scans at the indicated time points showing tumor burden in EML4-ALK lung cancer mice treated by crizotinib. Multiple scans from a total of 4 mice are shown. Supplemental Figure 2. Representative …
View article: Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC
Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC Open
Supplemental Figure 2. FGFR2/CC10 staining of 20 and 32 week FGFR2 lung tumors.
View article: Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC
Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC Open
Descriptions of each of the Supplemental Figures/Tables
View article: Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC
Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC Open
Supplemental Table 2. p53 status and relation to tumor penetrance.
View article: Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC
Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC Open
Supplemental Table 1. Patients (SqCC and AdC) with FGFR2 mutations.
View article: Data from <i>FOXO3</i> Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma
Data from <i>FOXO3</i> Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma Open
The FOXO family of transcription factors elicits cell cycle arrest, apoptosis, and resistance to various physiologic and pathologic stresses relevant to sporadic cancer, such as DNA damage and oxidative stress. Although implicated as tumor…
View article: Supplementary Figure 1 from <i>FOXO3</i> Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma
Supplementary Figure 1 from <i>FOXO3</i> Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma Open
Supplementary Figure 1 from FOXO3 Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma
View article: Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC
Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC Open
Supplemental Figure 3. Extracellular Domain FGFR2 mutant mouse IHC.
View article: Supplementary Figure 3 from <i>FOXO3</i> Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma
Supplementary Figure 3 from <i>FOXO3</i> Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma Open
Supplementary Figure 3 from FOXO3 Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma
View article: Supplementary Figure 4 from <i>FOXO3</i> Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma
Supplementary Figure 4 from <i>FOXO3</i> Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma Open
Supplementary Figure 4 from FOXO3 Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma
View article: Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC
Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC Open
Supplemental Table 1. Patients (SqCC and AdC) with FGFR2 mutations.
View article: Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC
Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC Open
Supplemental Figure 3. Extracellular Domain FGFR2 mutant mouse IHC.
View article: Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC
Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC Open
Supplemental Figure 2. FGFR2/CC10 staining of 20 and 32 week FGFR2 lung tumors.
View article: Supplementary Figure 4 from <i>FOXO3</i> Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma
Supplementary Figure 4 from <i>FOXO3</i> Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma Open
Supplementary Figure 4 from FOXO3 Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma
View article: Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC
Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC Open
Supplemental Table 2. p53 status and relation to tumor penetrance.
View article: Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC
Data Supplement from Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC Open
Supplemental Figure 1. Details about genetically engineered mouse model, with gross tumor lesions present in lung followed about negative FGFR2 IHC (control) and before/after BGJ-398 treatment.
View article: Supplementary Figure 2 from <i>FOXO3</i> Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma
Supplementary Figure 2 from <i>FOXO3</i> Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma Open
Supplementary Figure 2 from FOXO3 Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma